Scientific article

Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l'évaluation de la balance bénéfice-risque

Published inRevue médicale suisse, vol. 12, no. 510, p. 561-566
Publication date2016

Studies report that between 6 and 13% of women experience symptoms of depression during pregnancy and the postpartum period. The abundant data available make selective serotonin reuptake inhibitors (SSRIs) the first line treatment in pregnancy when a pharmacological treatment is required. Risks associated with the use of SSRIs during pregnancy are limited (moderate effect size) and are often not distinguishable from those inherent to the mother's disease. Yet, several questions regarding the SSRI safety profile for the unborn child are still under debate or require additional epidemiological data. The decision of SSRI use during pregnancy needs an individual evaluation of the risk-benefit balance.

  • Antidepressive Agents/adverse effects/therapeutic use
  • Depressive Disorder/complications/drug therapy
  • Female
  • Humans
  • Practice Patterns, Physicians'
  • Pregnancy
  • Pregnancy Complications/chemically induced/drug therapy/psychology
  • Risk Assessment
  • Serotonin Uptake Inhibitors/adverse effects/therapeutic use
Citation (ISO format)
WEISSKOPF, Etienne et al. Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l’évaluation de la balance bénéfice-risque. In: Revue médicale suisse, 2016, vol. 12, n° 510, p. 561–566.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation07/27/2017 10:19:00 AM
First validation07/27/2017 10:19:00 AM
Update time03/15/2023 2:15:01 AM
Status update03/15/2023 2:15:00 AM
Last indexation01/17/2024 1:10:42 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack